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Aims:MicroRNAs (miRNAs) play important roles in several biological processes. In this study, we investigated the
role of miR-1, an endothelin-1 (ET-1) targetingmiRNA, in endothelial cells (ECs) and tissues of diabetic animals.
ET-1 is known to be of pathogenetic signiﬁcance in several chronic diabetic complications.
Main methods: PCR array was used to identify alterations of miRNA expression in ECs exposed to glucose. miR-1
expression was validated by TaqMan real-time PCR assay. Human retinal ECs (HRECs) and human umbilical vein
ECs (HUVECs) exposed to various glucose levels with or without miR-1 mimic transfection, and tissues from
streptozotocin-induced diabetic animals after two months of follow-up, were examined for miR-1 expression,
as well as ET-1 and ﬁbronectin (FN) mRNA and protein levels.
Key ﬁndings: Array analyses showed glucose-induced alterations of 125 miRNAs (out of 381) in ECs exposed to
25 mM glucose compared to 5 mM glucose. Fifty-one miRNAs were upregulated and 74 were downregulated.
25 mMglucose decreasedmiR-1 expression and increased ET-1mRNA and protein levels. miR-1mimic transfec-
tion prevented HG-induced ET-1 upregulation. Furthermore, glucose induced upregulation of FN, which ismedi-
ated partly by ET-1, was also prevented by such transfection.
Diabetic animals showed decreasedmiR-1 expression in the retina, heart and kidneys. In parallel, ET-1mRNA ex-
pressions were increased in these tissues of diabetic animals, in association with upregulation of FN.
Signiﬁcance: These results indicate a novel glucose-induced mechanism of tissue damage, in which miR-1 regu-
lates ET-1 expressions in diabetes. Identifying such mechanisms may lead to RNA based treatment for diabetic
complications.
© 2014 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
MicroRNAs (miRNAs) are highly conserved, ~22 nt long RNA
molecules encoded in the genomes of plants and animals that negative-
ly regulate gene expression (Bartel, 2009; Cuellar andMcManus, 2005).
Investigations have demonstrated the importance of miRNA-mediated
regulation of gene expression in several disease processes, such as dia-
betes, cancer and neurodegeneration (Feng et al., 2013; Hashimoto
et al., 2013; Thomson et al., 2011). miRNAs have emerged as a major
mechanism in regulating basal and stress-induced alterations of gene
expression. They are important in controlling cellular differentiation,
proliferation, and apoptosis, as well as in providing feedback loops for
various signal transduction pathways (Cuellar and McManus, 2005).
miRNAs interact with the 3′ untranslated region (3′UTR) of their target
mRNA and negatively regulate gene expression post-transcriptionally
(Bartel, 2009). Mature miRNA sequences are highly conserved amongn the wrong issue. The article is
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-NC-ND license.species and a single gene may be regulated by many different miRNAs
(Soon and Kiaris, 2013). Conversely, one miRNA may regulate a large
number of target genes (Soon and Kiaris, 2013; Rege et al., 2013).
Recent data from our and other laboratories have demonstrated the
role of miRNA alterations in diabetic complications (McArthur et al.,
2011; Feng et al., 2011; Putta et al., 2012; Feng and Chakrabarti, 2012;
Natarajan et al., 2012). We have also shown that other epigenetic
changes, such as histone acetylation, also interact withmiRNAs inmedi-
ated transcriptional regulation in diabetes (McArthur et al., 2011). Data
from our laboratory has demonstrated the role of several miRNAs in
chronic diabetic complications (McArthur et al., 2011; Feng et al., 2011).
To this extent,wehave shown thatmiR-200b regulates VEGF and controls
blood vessel permeability and angiogenesis in diabetic retinopathy
(McArthur et al., 2011). We have also shown that miR-146a regulates in-
creased extracellular matrix protein production in diabetic retinopathy
and nephropathy (Feng et al., 2011). Finally, we and others have demon-
strated alterations ofmiR-133a in cardiomyocyte hypertrophy in diabetes
(Feng et al., 2010; Yildirim et al., 2013; Chavali et al., 2012).
Chronic diabetes leads to both structural and functional damage
in the vasculature and causes secondary complications, including
retinopathy, nephropathy, cardiomyopathy, and peripheral vascular
disease. Endothelial cells (ECs) are the primary targets of glucose-
induced cellular damage in chronic diabetic complications due to
Table 1
Oligonucleotide sequences for RT-PCR.
Gene Sequence (5′→ 3′)
ET-1 5′ AAGCCCTCCAGAGAGCGTTAT 3′
5′ CGAAGGTCTGTCACCAATGT 3′
6FAM-TGACCCACAACCGAG-GBNFQ
FN-1 5′ GATAAATCAACAGTGGGAGC 3′
5′ CCCAGATCATGGAGTCTTTA 3′
β-Actin 5′ CATCGTACTCCTGCTTGCTG 3′
5′ CCTCTATGCCAACACAGTGC 3′
276 B. Feng et al. / Life Sciences 118 (2014) 275–280their innate ability to uptake glucose independent of insulin activity
(Giacco and Brownlee, 2010; Madonna and De Caterina, 2011). Hy-
perglycemia induced oxidative stress is known to activate multiple
signaling pathways which converge onto the cell nucleus, leading
to increased expression of multiple genes causing EC dysfunction
(Kunsch and Medford, 1999). EC dysfunction may lead to increased
permeability and increased extracellular matrix (ECM) production.
In particular, ECM alterations and basement membrane (BM) thicken-
ing are structural hallmarks of diabetic complications. An important
mediator of these ECM alterations is endothelin-1 (ET-1). We and
others have demonstrated upregulation of ET-1 in ECs and in organs af-
fected by chronic diabetic complications (Khan and Chakrabarti, 2007;
Chen et al., 2007; Sagar et al., 2013; Ergul, 2011). Furthermore, we
have previously demonstrated that miR-320 regulates glucose induced
ET-1 expression in indirectly through ERK1/2 signaling in ECs (Feng and
Chakrabarti, 2012).
In the present study we investigated the role of miRNA regulation
on ET-1, as well as its downstream target ﬁbronectin (FN), in diabetic
complications. We chose to focus on a speciﬁc miRNA, miR-1, which
was found reduced in an array analysis following glucose exposure.
miR-1 has widespread biological effects as it regulates multiple im-
portant transcripts. miR-1 has shown to be of importance in cardiac
hypertrophy (Karakikes et al., 2013). Recently it has also been demon-
strated that miR-1 is important in cardiomyocyte apoptosis in diabetes
(Shan et al., 2010). In addition, it has been shown to be of importance in
multiple malignancies (Hudson et al., 2012; Li et al., 2012). Based on
bioinformatic analysis, miR-1 is predicted to regulate ET-1 (www.
microrna.org). However, it is unclear if this potential regulatory rela-
tionship is relevant in respect to diabetic complications.
We focused on miR-1 in the regulation of ET-1 in glucose induced
EC damage. As mentioned, ECs are primary targets for damage in di-
abetic complications. Thus, we used both microvascular Human Ret-
inal Endothelial Cells (HRECs) and macrovascular Human Umbilical
Vein Endothelial Cells (HUVECs) for this study. We have previously
demonstrated glucose-induced alterations of gene expression in
these cells (McArthur et al., 2011; Feng et al., 2011; Feng and
Chakrabarti, 2012). We further expanded our analysis to the tissues
from the diabetic animals. We hypothesize that downregulation of
miR-1 in response to glucose induction mediates ET-1 upregulation,
which then has wide-ranging downstream effects on ECM genes, such
as FN, thus facilitating ECM accumulation in diabetic complications.
Materials and methods
Animals
All animals were cared for according to the Guiding Principle in the
Care and Use of Animals. All experimentswere approved by the Univer-
sity of Western Ontario Council on Animal Care Committee. Male
C57BL/6 mice (20–25 g) were obtained from the Charles River Colony
(Wilmington,MA, USA) andwere randomly divided into control and di-
abetic groups.Methods of diabetes induction using streptozotocin (STZ)
andmonitoring have previously been described (McArthur et al., 2011).
After 8 weeks, the animals (n = 8/group) were sacriﬁced. The retinal,
heart and renal cortical tissues were collected for gene and protein ex-
pression and miRNA analysis.
Cell culture and treatments
All reagents were purchased from Sigma (Oakville, Ontario, Canada)
unless speciﬁed. Human retinal microvascular endothelial cells (HRECs)
were obtained from Olaf Pharmaceuticals (Worchester, MA). HUVECs
were obtained from Bio-Whittaker (San Diego, CA). ECs were grown
in endothelial cell basal medium 2 (EBM-2, Lonza, Walkersville, MD)
supplemented with 5% fetal bovine serum, endothelial cell growth sup-
plement (Bio-Whittaker), and 100 μg/ml penicillin/streptomycin. Cells
were plated at a density of 1 × 105 cells/ml. They were treated withvarious levels of D-glucose. No insulin was present in any media. All
cells were maintained in a humidiﬁed atmosphere containing 5%
CO2 at 37 °C incubation and were passaged in 6 well plates (Corning,
Acton, MA). Cells were treated with various levels of D-glucose or
25 mmol L-glucose (osmotic control) for 48 h.
After 24 h in serum-free, cells were transfected with miRIDIAN
microRNA mimic miR-1 (100 nM) (DHARMACON Inc., Chicago, IL,
USA) using transfection reagent Lipofectamine 2000 (Invitrogen,
ON, Canada). Negative control miRNA (100 nM) was used for control
transfection.
Microarray analysis for miRNA expression
Total miRNAs were extracted from ECs using the mirVana miRNA
isolation kit (Ambion, Inc., Austin, TX, USA), according to the
manufacturer's instruction. Brieﬂy, the cells were collected and
lysed in the Lysis/Binding solution. miRNA additive (1:10) was
added to the lysate and incubated for 10 min on ice. And equal vol-
ume acid-phenol:chloroformwas added to the lysate. Following cen-
trifugation and removal of the aqueous phase, ethanol was added
into the mixture. This mixture was passed through the ﬁlter car-
tridge, washed several times with ethanol solutions and total RNA
was eluted with the provided elution buffer.
miRNA expression proﬁling was performed following the
manufacturer's protocol (Life Technologies, ON, Canada). In brief,
1 μg of isolated total miRNA was added with Megaplex™ RT primer,
dNTPs, MultiScribe™ reverse transcriptase, RNase inhibitor, buffer to
perform Megaplex reverse transcription. Following reverse transcrip-
tion, the real-time PCR reaction mixture was prepared by mixing the
Megaplex RT product with TaqMan universal PCR master mix, No
AmpErase UNG (2×). The PCR reaction mixture was dispensed into
each port of the TaqMan miRNA array card to run the array using the
384 well TaqMan low density array default thermal-cycling conditions
in the 7900HT system (Life Technologies, ON, Canada). The results
were showed using relative quantiﬁcation (ΔΔCt).
miRNA validation by real time RT-PCR
Reverse transcription was performed after isolating of miRNA (Life
Technologies Inc., ON, Canada). TaqMan™ miR-1 assay (Ambion Inc.,
Austin, TX, USA) was used with quantitative real-time PCR (qRT-PCR)
to analyze the expression of miR-1, in accordance with the
manufacturer's instructions. Normalization was performed to U6
snRNA to account for differences in reverse-transcription efﬁciencies
and amount of template in the reaction mixtures.
Real time RT-PCR for mRNA
RNAwas extracted with TRIzol™ reagent (Invitrogen Canada Inc.,
ON, Canada) as previously described (McArthur et al., 2011; Feng
et al., 2011). Total RNA (2 μg) was used for cDNA synthesis with
cDNA reverse transcription kit (Applied Biosystems Inc., CA, USA)
and was performed using a Roche LightCycler 96 as previously de-
scribed (Putta et al., 2012; Feng and Chakrabarti, 2012) (Roche Diag-
nostics Canada, QC, Canada). The primer sequences have been listed
in Table 1. β-Actin mRNA was used as an internal control for
normalization.
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Supernatants were collected from cultured ECs. ELISA for FN was
performed using a commercially available kit (Millipore, CA, USA) ac-
cording to the manufacturer's instructions. Similarly ET-1 was mea-
sured using speciﬁc ELISA kit (Enzo Life Sciences, Inc., NY, USA)
following the manufacturer's instructions.
Statistical analysis
All experimental data are expressed as means ± SE and were ana-
lyzed by ANOVA or Student t-test as appropriate. A p value of 0.05 or
less was considered signiﬁcant.
Results
miR-1 is downregulated in ECs exposed to elevated glucose levels in
association with increased ET-1 and FN
Since hyperglycemia initiates damage in ECs, we focused our inves-
tigation on these cells. To this extent we screened two endothelial cell
types, HRECs, a microvascular EC, and HUVECs, a macrovascular EC.
To examine glucose related change in ET-1 expression, we investi-
gated ET-1 mRNA expression in the HUVECs. We examined ET-1
mRNA levels at various glucose conditions. A dose dependent ET-1
mRNA upregulation was seen with various glucose levels, peaking
at 25 mM glucose. No change was seen in 25 mM L-glucose (osmotic
control). Then data are keeping with previous studies from ours and
multiple other laboratories (McArthur et al., 2011; Feng et al., 2011;
Feng and Chakrabarti, 2012; McGinn et al., 2003; Peng et al., 2013;
Tien et al., 2013). Hence, in subsequent experiments we used 5 mM
glucose (simulating nomoglycemia) and 25 mM glucose (simulating
hyperglycemia). Similar concentrations of glucose are also common-
ly used in such studies by several laboratories (McArthur et al., 2011;
Feng et al., 2011; Feng and Chakrabarti, 2012; McGinn et al., 2003;
Peng et al., 2013; Tien et al., 2013). 25 mM glucose further causedFig. 1. 25 mM D-glucose caused a dose-dependent increase in A) ET-1 mRNA and B) FN mR
25 mM glucose showed C) increased ET-1 protein and D) FN protein level by ELISA, compa
expression [n = 6/group * = signiﬁcantly different from 5 mM D-glucose; mRNA levels a
(U6). 25 mM L-glucose was used as osmotic control].upregulation of FN, a downstream target of ET-1 (Fig. 1). We then ex-
amined weather such mRNA changes are associated with alterations
of protein levels. ELISA analysis demonstrated glucose induced upregu-
lation of protein levels of ET-1 and FN (Fig. 1). Similarly 25 mM glucose
induced changeswere presented in HRECs. In parallel, we examined the
alterations inmiRNA expression between ECs exposed to 5 mMglucose
and 25 mM glucose using a miRNA PCR-array. We observed alterations
of 125 miRNAs (out of 381) in ECs exposed to 25 mM glucose (HG)
compared to 5 mM glucose. Fifty-one miRNAs were upregulated and
74 were downregulated (Suppl. Table 1).
Several open sourced softwares (www.TargetScan.org, www.
microrna.org, www.ebi.ac.uk1) were used for miRNA target predic-
tions. miR-1, identiﬁed to be signiﬁcantly downregulated in the ECs
exposed to 25 mM glucose, was found to be associated with ET-1.
We veriﬁed the downregulation of miR-1 with qRT-PCR in both
HRECs and HUVECs (Figs. 1, 2). No change in miR-1 level was observed
when the cells were challenged with 25 mM L-glucose (osmotic
control).
miR-1 regulates glucose induced upregulation of ET-1 and ECM protein in
the ECs
To establish a cause–effect relationship, we chose to focus on HRECs
as an in vitro model system, as microvascular endothelial damage af-
fecting the retina is of particular clinical signiﬁcance. We and others
have shown that ECs exposed to high levels of glucose (simulating hy-
perglycemia) recapitulate molecular and functional features of diabetic
vascular pathologies, including upregulation of ET-1 and FN (McArthur
et al., 2011; Feng et al., 2011; Giacco and Brownlee, 2010;Madonna and
De Caterina, 2011; Kunsch and Medford, 1999).
In parallel to decreasedmiR-1 level upon exposure to 25 mM glu-
cose conditions, mRNA levels of ET-1 were increased. Such increases
were prevented by miR-1 mimic transfection (Fig. 2). Transfection
efﬁciency, assessed by measuring miR-1 expression with qRT-PCR,NA expression by real time RT-PCR in the HUVECs. Furthermore, HUVECs exposed to
red to 5 mM D-glucose. E) 25 mM D-glucose also caused signiﬁcant reduction of miR-1
re expressed as a ratio to β-actin, miRNA levels are expressed as a ratio to U6 snRNA
Fig. 2. In theHRECs, 25 mMglucose caused decreased A)miR-1 expression and increased B) ET-1mRNA and C) FNmRNA expression by real time RT-PCR. Furthermore, HRECs exposed to
25 mMglucose showedD) increased ET-1 protein and E) FNprotein level by ELISA, compared to 5 mMglucose. Such increaseswere prevented bymiR1-mimic (miR-1) transfection (B–E)
[25 mM L-glucosewas used as osmotic control, n = 6/group * = signiﬁcantly different from 5 mMD-glucose;mRNA levels are expressed as a ratio to β-actin, miRNA levels are expressed
as a ratio to U6 snRNA (U6), scrambled = scrambled miR control transfection].
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to scrambled miRNA transfection. We did similar experiments with
ECMmatrix protein FN as we have shown FN is a downstream target
of ET-1 in hyperglycemia. Glucose induced FNmRNA upregulation in
the HRECs was signiﬁcantly prevented by miR-1 mimic transfection
(Fig. 2).
As microRNAs are post-transcriptional modiﬁers, we further ex-
amined protein levels of FN and ET-1 using ELISA. In parallel to the
mRNA data, miR-1 transfection prevented glucose-induced upregula-
tion of FN and ET-1. No effects were seen when cells were transfected
with scrambled mimic (Fig. 2).miR-1 is downregulated in the tissues of diabetic animals: in association
with increased ET-1
We then wanted to see whether such changes are indeed of sig-
niﬁcance in a clinically relevant model of diabetic complications. To
this extent, STZ-induced diabetic mice showed hyperglycemia
(blood glucose of diabetics 23.0 ± 3.6 mmol/L vs controls 7.4 ±
1.1 mmol/L, p b 0.01) and reduced body weight (body weight of di-
abetics 29.4 ± 2.1 g vs controls 23.5 ± 1.3 g, p b 0.001). We exam-
ined retinal, renal cortical and cardiac tissues from STZ diabetic mice,
two months after onset of diabetes. All of these tissues are targets of
chronic diabetic complications and augmented ET-1 induced in-
creased ECM protein FN production has been previously demonstrat-
ed in these organs (Khan and Chakrabarti, 2007; McGinn et al.,
2003). Diabetic animals showed hyperglycemia, glucosuria and re-
duced body weight gain (data not shown). Analyses of miR-1 levels
demonstrated signiﬁcantly decreased levels in retinal, cardiac andrenal tissues of these animals (Fig. 3). Such reductions were associat-
ed with increased levels of ET-1 and FN (Fig. 3).Discussion
In this research, we have described a novel mechanism of ET-1 reg-
ulation in diabetes. Using both in vivo and in vitro systems, we demon-
strated that that miR-1 is downregulated in ECs following exposure to
high glucose and in the target organs affected by chronic diabetic com-
plications. Furthermore, this process leads to glucose-induced upregula-
tion of ET-1, a key mechanism bywhich extracellular matrix protein FN
is regulated in diabetes. Following initial identiﬁcation of glucose in-
duced down-regulation of miR-1 by a PCR based array, in association
with upregulation of ET-1 and FN, we validated such changes in two dif-
ferent endothelial cell systems.We further established functional signif-
icance of these changes at the mRNA and protein levels using miR-1
mimic transfection and normalized glucose-induced upregulation of
ET-1. Our data indicates that miR-1 regulates glucose-induced ET-1 up-
regulation in the ECs and that such process mediates ECM protein FN
production. It has to be noted that FN is not a direct target of miR-1
(www.targetscan.org), but is induced following ET-1 induction by
high glucose.
We used two well-characterized ECs to identify the in vitro biologic
signiﬁcance. These are well-studied cell systems in vascular biology, in-
cluding the study of diabetic complications (Onat et al., 2011). To study
functional signiﬁcance we used HRECs, which are of signiﬁcance in the
context of a major chronic diabetic complication, i.e., diabetic retinopa-
thy. In parallel, we demonstrated importance of this process in the ret-
ina, kidneys and heart of diabetic animals, in a well-established model
Fig. 3. STZ induced diabetes (2 months follow-up) caused (A–C) decreasedmiR-1 expression in the retina, heart and kidney, and (D–F) increased ET-1mRNA expression in these organs,
compared to age and sex-matched controls by quantitative RT-PCR [mRNA levels are expressed as a ratio to β-actin andmiR levels are expressed as a ratio to U6 snRNA (U6),* = p b 0.05
compared to control; n = 6–8/treatment; C = control, D = STZ diabetes].
Fig. 4. A summary diagram showing the possible mechanisms of ET-1 regulation through
miR-1.
279B. Feng et al. / Life Sciences 118 (2014) 275–280of chronic diabetic complications (Tesch and Allen, 2007; Shen and
Bornfeldt, 2007).
Although miR-1 alteration has recently been described in other bio-
logical and disease processes, this is the ﬁrst report of miR-1 mediated
ET-1 regulation in the context of chronic diabetic complications. Re-
cently it has been shown that miR-1 inhibits proliferation of hepato-
cellular carcinoma cells through modulating ET-1 (Li et al., 2012). In
the context of chronic diabetic complications, miR-1 downregulation
has been shown to contribute to diabetes induced oxidative stress
through regulation of junctin (Yildirim et al., 2013). Also, miR-1
has been thought to be a mediator of non-diabetic cardiac hypertro-
phy (Fichtlscherer et al., 2011). Circulating miR-1 levels have been
correlated with occurrence of myocardial infarction (Ai et al., 2010).
The current study demonstrates potential therapeutic implica-
tion of miR-1 in chronic diabetic complications, as it is altered in
multiple organs affected by chronic diabetic complications. It is pos-
sible that manipulation of miR-1 may work through alteration of ET-
1 as well as several other molecules as described above. Most target
mRNA predictions for miRNAs stem from computational analysis ex-
amining sequence complementarity (Vlachos and Hatzigeorgiou,
2013). It is well accepted that a single miRNA (e.g. miR-1) has multiple
targets. This may be an advantage in therapy, as multiple genes can be
corrected. However, at the same time, these interactionsmay pose ther-
apeutic challenges via off-target effects. As seen in this study, the levels
ofmiR-1 alteration do not parallel ET-1 level (Figs. 1, 2). Exact reason for
this discrepancy is not known. As noted above that multiple miRNAs
may control a single transcript. Hence it is possible that simultaneously
other miRs are controlling ET-1 expression, producing additional ef-
fects. In keeping with this notion, we have previously showed that
miR-320 also regulates glucose induced ET-1 upregulation (Feng and
Chakrabarti, 2012).
As functions of various miRNAs and their role in biological pro-
cesses become clearer, several of them appear to play signiﬁcant
roles in chronic diabetic complications. We have previously demon-
strated the role of miR-133a in diabetic cardiomyopathy (Feng et al.,
2010). Other investigators have shown the role of miR-192 in diabet-
ic nephropathy (Putta et al., 2012; Kato et al., 2007). We have also re-
cently demonstrated downregulation of miR-200b and miR-146a in
several chronic diabetic complications (McArthur et al., 2011; Fenget al., 2011). The mechanisms which hyperglycemia causes cellular
damage in the context of chronic diabetic complications are indeed
complex and are not fully understood. However, it is accepted that
glucose-induced oxidative stress plays an important role (Giacco
and Brownlee, 2010; Madonna and De Caterina, 2011; Kaur et al.,
2006). Such oxidative stress causes DNA damage and modiﬁes tran-
scription machinery through the activation of the redox-sensitive
transcription factors (Matsumoto et al., 2008). Increased oxidative
stress causes and altered expression of a number of genes, including
ET-1 (McGinn et al., 2003; Matsumoto et al., 2008). All such transcripts
may however be post transcriptionally regulated by miRNAs. Hence,
miRNAs lend themselves to be therapeutic agents. However, the chal-
lenge for miRNA research is to deﬁne the function of speciﬁc miRNAs
in various tissues and in the context of speciﬁc disease states.
In summary, we have identiﬁed a speciﬁc miRNA, i.e., miR-1, that
has importance in regulating ET-1 in chronic diabetic complications.
A possible mechanistic summary diagram has been presented in Fig. 4.
Understanding such novel pathways will help to better understanding
280 B. Feng et al. / Life Sciences 118 (2014) 275–280of the pathogenesis of chronic diabetic complications and will pave the
way towards the development of novel adjuvant treatments.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.lfs.2013.12.199.
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